COR Therapeutics Betters Estimate
In the year-earlier period, the biotech posted a loss of 19 cents a share. Revenue climbed 27% to $22.8 million from $17.9 million.
The company also again said it expects to earn 35 cents to 37 cents a share this year. Analysts expect that it'll earn 34 cents a share, according to Thomson Financial/First Call.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts